P-Glycoprotein: A Clue to Vitamin K Antagonist Stabilization

Pharmacogenomics - United Kingdom
doi 10.2217/pgs.14.164
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Future Medicine Ltd

Related search

Vitamin K Antagonist Embryofetopathy

2020English

Pharmacological Profile of Non-Vitamin K Antagonist Oral Anticoagulants

African Journal of Pharmacy and Pharmacology
2017English

Pharmacokinetics and Pharmacodynamics of Tecarfarin, a Novel Vitamin K Antagonist Oral Anticoagulant

Thrombosis and Haemostasis
Hematology
2017English

Safety of Switching From Vitamin K Antagonist to Non-Vitamin K Antagonist Oral Anticoagulant in Frail Elderly With Atrial Fibrillation: Rationale and Design of the FRAIL-AF Randomised Controlled Trial

BMJ Open
Medicine
2019English

Physician's Hand on the International Normalized Ratio Level of Vitamin K Antagonist

Journal of Arrhythmia
Cardiovascular MedicineCardiology
2019English

Pcv135 - Non-Vitamin K Antagonist Oral Anticoagulants Prescription Monitoring: How to Optimize Vigilance in Stroke Prevention

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Use of Non-Vitamin K Antagonist Oral Anticoagulants 2008-2016: A Danish Nationwide Cohort Study

Basic and Clinical Pharmacology and Toxicology
MedicineToxicologyPharmacology
2018English

P-Glycoprotein (ABCB1) Limits the Brain Distribution of YQA-14, a Novel Dopamine D3 Receptor Antagonist

Chemical and Pharmaceutical Bulletin
MedicineDrug DiscoveryChemistry
2015English

Vitamin K Antagonist Therapy Is a Risk Factor for Ulcer Development and Death Among Dialyzed Patients

Therapeutic Apheresis and Dialysis
HematologyNephrology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy